Table 1 Comparison of patients’ demographic and clinical features at baseline and after the end of the trial between the two groups
Variables | Topiramate (n) | Metformin (n) | χ2/t | P value |
|---|---|---|---|---|
n | 32 | 30 | Â | |
Gender (M1/F) | 28/4 | 24/6 | 0.64 | > 0.05 |
Age (years) | 32.81 ± 9.11 | 31.87 ± 8.48 | 0.42 | > 0.05 |
Marital status (M2/S1/D) | 9 /22 /1 | 11 /16 /3 | 2.09 | > 0.05 |
Occupation (F/J/E) | 15 /13 /4 | 16 /8 /6 | 1.56 | > 0.05 |
Level of education | Â | Â | Â | Â |
 Primary education | 15 | 13 | 0.44 | > 0.05 |
 Secondary education | 15 | 16 |  |  |
 College and above | 2 | 1 |  |  |
Parental obesity | Â | Â | Â | Â |
 No/yes | 29/3 | 28/2 | 0.15 | > 0.05 |
Diagnosis (S2/AD) | 31/1 | 27/3 | 1.21 | > 0.05 |
Inpatients/outpatients | 2/30 | 0/30 | 1.94 | > 0.05 |
The number of patients with/without loss of follow-up | ||||
 With/without loss of follow-up at week 4 | 5/27 | 10/20 | 2.65 | > 0.05 |
 With/without loss of follow-up at week 8 | 6/26 | 11/19 | 2.50 | > 0.05 |
 With/without loss of follow-up at week 12 | 15/17 | 13/17 | 0.08 | > 0.05 |
 With/without loss of follow-up at week 16 | 22/10 | 15/15 | 2.26 | > 0.05 |
CPZ equivalent daily dose of all APS used during the trial | 433.75 ± 215.57 | 370.17 ± 177.07 | 1.26 | > 0.05 |
The main types of APS currently in use during the trial | ||||
 Clozapine | 16 | 10 | 3.15 | > 0.05 |
 Olanzapine | 6 | 6 |  |  |
 Quetiapine | 2 | 5 |  |  |
 Risperidone | 4 | 6 |  |  |
 Other APS, and etc. | 4 | 3 |  |  |
Daily dosage of clozapine during the trial (n: 16, 10) | 229.69 ± 121.18 | 165 ± 114.99 | 1.35 | > 0.05 |
Daily dosage of olanzapine during the trial (n: 6, 6) | 10.0 ± 6.32 | 12.08 ± 5.10 | 0.63 | > 0.05 |